Фармацевтична опіка за больового синдрому: оцінка обізнаності фармацевтів щодо застосування нестероїдних протизапальних препаратів і профілактики їхніх ускладнень

Nonsteroidal anti-inflammatory drugs (NSAIDs) remain one of the most commonly used groups of medications for the symptomatic treatment of pain syndrome. The widespread use of NSAIDs, particularly in the context of self-medication, requires special attention to the aspects of safe and rational use of these drugs within the framework of pharmaceutical care. The aim of the study – to assess the level of pharmacists’ awareness regarding the use of NSAIDs for the symptomatic treatment of pain syndrome, the prevention of adverse effects, and the development of approaches to safe and rational self-medication within the framework of pharmaceutical care. A questionnaire survey was conducted. The questionnaire included questions regarding the practice of NSAID recommendations, the choice of dosage forms, the prevention of adverse effects, and the identification of risk factors for their development. The responses were analyzed using descriptive statistics.

As a result, most pharmacists are actively involved in the process of pharmaceutical care for patients with pain syndrome. When selecting NSAIDs, respondents prioritize effectiveness, safety, availability, and pharmacotherapeutic properties. The main risks associated with NSAID use, as identified by the pharmacists, include the development of gastropathies, nephropathies, and cardiovascular complications. To prevent adverse effects, pharmacists emphasize the need to minimize the dosage and duration of therapy, recommend the use of gastroprotective agents and probiotics, and consider comorbid conditions.

Thus, results highlight the importance of improving pharmacists’ professional knowledge regarding the safe use of NSAIDs, the prevention of complications, and patient information about the risks of self-medication. It is recommended to implement periodic educational initiatives for pharmacists with an emphasis on clinical vigilance, a personalized approach to NSAID recommendations, and increased responsibility for the prevention of adverse effects in patients.

https://doi.org/10.33250/19.04.399

pdf (Українська)

References

1. GBD 2021 Other musculoskeletal disorders collaborators. Global, regional, and national burden of other musculoskeletal disorders, 1990–2020, and projections to 2050: a systematic analysis of the Global Burden of Disease Study 2021. The Lancet. Rheumatology. 2023. V. 5 (11). P. e670–e682.
https://doi.org/10.1016/S2665-9913(23)00232-1.
2. Perrot S., Anne-Priscille T. Pain in osteoarthritis from a symptom to a disease. Best practice & research. Clinical rheumatology. 2023. V. 37 (2). P. 101825. https://doi.org/10.1016/j.berh.2023.101825.
3. Evaluating quality of life across different stages of rheumatoid arthritis. Z. Haq ul, B. A. Butt, N. Zafar et al. Journal of Fatima Jinnah Medical University. 2024. V. 18 (3). P. 103–107. https://doi.org/10.37018/CYIE3425.
4. Fibromyalgia: a review of the pathophysiological mechanisms and multidisciplinary treatment strategies. L. N. Jurado-Priego, C. Cueto-Ureña, M. J. Ramírez-Expósito, J. M. Martínez-Martos. Biomedicines. 2024. V. 12 (7). P. 1543. https://doi.org/10.3390/biomedicines12071543.
5. Alfaifi S., Arakawa N., Bridges S. The relevance of the International Pharmaceutical Federation Global Competency Framework in developing a country-level competency framework for pharmacists: a cross-sectional study. Exploratory research in clinical and social pharmacy. 2021. V. 5. P. 100095.
https://doi.org/10.1016/j.rcsop.2021.100095.
6. Bindu S., Mazumder S., Bandyopadhyay U. Non-steroidal anti-inflammatory drugs (NSAIDs) and organ damage: a current perspective. Biochemical pharmacology. 2020. V.180. P. 114147. https://doi.org/10.1016/j.bcp.2020.114147.
7. Належна аптечна практика: Стандарти якості аптечних послуг (Спільна настанова МФФ/ВООЗ з НАП). URL: https://zakon.rada.gov.ua/laws/show/897_009.
8. Lanas A., Chan, F. K. L. Peptic ulcer disease. Lancet (London, England). 2017. V. 390 (10094). P. 613–
624. https://doi.org/10.1016/S0140-6736(16)32404-7.
9. Conaghan P. G. A turbulent decade for NSAIDs: update on current concepts of classification, epidemiology, comparative efficacy, and toxicity. Rheumatology international.2012. V. 32 (6). P. 1491–1502. https://doi.org/10.1007/s00296-011-2263-6.
10. Glucuronidation of nonsteroidal anti-inflammatory drugs: identifying the enzymes responsible in human liver microsomes. G. E. Kuehl, J. W. Lampe, J. D. Potter, Bigler J. Drug metabolism and disposition: the biological fate of chemicals. 2005. V. 33 (7). P. 1027–1035. https://doi.org/10.1124/dmd.104.002527.
11. Marnett L. J. The COXIB experience: a look in the rearview mirror. Annual review of pharmacology and toxicology. 2009. V. 49. P. 265–290. https://doi.org/10.1146/annurev.pharmtox.011008.145638.
12. Mefenamic acid induced nephrotoxicity: an animal model. M. N. Somchit, F. Sanat, G. E. Hui et al. Advanced pharmaceutical bulletin. 2014. V. 4 (4). P. 401–404. https://doi.org/10.5681/apb.2014.059.
13. Pharmacological treatments for low back pain in adults: an overview of Cochrane Reviews. A. G. Cashin, B. M. Wand, N. E. O'Connell et al. The Cochrane database of systematic reviews. 2023. V. 4 (4). P. CD013815. https://doi.org/10.1002/14651858.CD013815.pub2.
14. Multidisciplinary guidelines for the rational use of topical non-steroidal anti-inflammatory drugs for musculoskeletal pain (2022). C. Shi, Z. Ye, Z. Shao et al. Journal of clinical medicine. 2023. V. 12 (4). P. 1544. https://doi.org/10.3390/jcm12041544.
15. Drug-associated gastropathy: diagnostic criteria. D. S. Bordin, M. A. Livzan, O. V. Gaus et al. Diagnostics (Basel, Switzerland). 2023. V. 13 (13). P. 2220. https://doi.org/10.3390/diagnostics13132220.
16. Goldstein J. L., Cryer B. Gastrointestinal injury associated with NSAID use: a case study and review of risk factors and preventative strategies. Drug, healthcare and patient safety. 2015. V. 7. P. 31–41. https://doi.org/10.2147/DHPS.S71976.
17. Coxib and traditional NSAID Trialists' (CNT) Collaboration. Vascular and upper gastrointestinal effects of non-steroidal anti-inflammatory drugs: meta-analyses of individual participant data from randomised trials. N. Bhala, J. Emberson, A. Merhi, et al. Lancet (London, England). 2013. V. 382 (9894).
P. 769–779. https://doi.org/10.1016/S0140-6736(13)60900-9.
18. Evaluating the mucoprotective effect of polydeoxyribonucleotide against indomethacin-induced gastropathy via the MAPK/NF-κB signaling pathway in rats. I. G. Ko, J. J. Jin, L. Hwang et al. European journal of pharmacology. 2020. V. 874. P. 172952. https://doi.org/10.1016/j.ejphar.2020.172952.
19. Watanabe T., Fujiwara Y., Chan F. K. L. Current knowledge on non-steroidal anti-inflammatory drug-induced small-bowel damage: a comprehensive review. Journal of gastroenterology. 2020. V. 55 (5). P. 481–495. https://doi.org/10.1007/s00535-019-01657-8.
20. Lanza F. L., Chan F. K., Quigley E. M. & Practice parameters committee of the American College of Gastroenterology. Guidelines for prevention of NSAID-related ulcer complications. The American journal of gastroenterology. 2009. V. 104 (3). P. 728–738. https://doi.org/10.1038/ajg.2009.115.
21. Targownik L. E., Fisher D. A., Saini S. D. AGA clinical practice update on de-prescribing of proton pump inhibitors: expert review. Gastroenterology. 2022. V. 162 (4). P. 1334–1342. https://doi.org/10.1053/j.gastro.2021.12.247.
22. Bifidobacterium breve Bif195 protects against small-intestinal damage caused by acetylsalicylic acid in healthy volunteers. B. Mortensen, C. Murphy, J. O'Grady et al. Gastroenterology. 2019. V. 157 (3). P. 637–646.e4. https://doi.org/10.1053/j.gastro.2019.05.008.
23. Basger B. J., Moles R. J., Chen T. F. Impact of an enhanced pharmacy discharge service on prescribing appropriateness criteria: a randomised controlled trial. International journal of clinical pharmacy. 2015. V. 37 (6). P. 1194–1205. https://doi.org/10.1007/s11096-015-0186-0.